Publications:

---

Two novel strategies to overcome the resistance to ALK tyrosine kinase inhibitor drugs: Macrocyclic inhibitors and proteolysis-targeting chimeras.

Medcomm

Song, Xiaoling X; Zhong, Hui H; Qu, Xiaojuan X; Yang, Linsong L; Jiang, Biao B

Publication Date: 2021-09

Variant appearance in text: ALK: L1204V

PubMed Link: 34766150

Variant Present in the following documents:

• Main text
• MCO2-2-341.pdf

View BVdb publication page

---

A Novel Sequentially Evolved EML4-ALK Variant 3 G1202R/S1206Y Double Mutation In Cis Confers Resistance to Lorlatinib: A Brief Report and Literature Review.

Jto Clinical And Research Reports

Zhu, Viola W VW; Nagasaka, Misako M; Madison, Russell R; Schrock, Alexa B AB; Cui, Jean J; Ou, Sai-Hong Ignatius SI

Publication Date: 2021-01

Variant appearance in text: ALK: L1204V

PubMed Link: 34589977

Variant Present in the following documents:

• Main text
• main.pdf

View BVdb publication page

---

Will the clinical development of 4th-generation "double mutant active" ALK TKIs (TPX-0131 and NVL-655) change the future treatment paradigm of ALK+ NSCLC?

Translational Oncology

Ou, Sai-Hong Ignatius SI; Nagasaka, Misako M; Brazel, Danielle D; Hou, Yujie Y; Zhu, Viola W VW

Publication Date: 2021-11

Variant appearance in text: ALK: L1204V

PubMed Link: 34365220

Variant Present in the following documents:

• Main text
• main.pdf

View BVdb publication page

---

TPX-0131, a Potent CNS-penetrant, Next-generation Inhibitor of Wild-type ALK and ALK-resistant Mutations.

Molecular Cancer Therapeutics

Murray, Brion W BW; Zhai, Dayong D; Deng, Wei W; Zhang, Xin X; Ung, Jane J; Nguyen, Vivian V; Zhang, Han H; Barrera, Maria M; Parra, Ana A; Cowell, Jessica J; Lee, Dong J DJ; Aloysius, Herve H; Rogers, Evan E

Publication Date: 2021-09

Variant appearance in text: ALK: L1204V

PubMed Link: 34158340

Variant Present in the following documents:

• Main text
• 1499.pdf

View BVdb publication page

---

Overcoming resistance by ALK compound mutation (I1171S + G1269A) after sequential treatment of multiple ALK inhibitors in non-small cell lung cancer.

Thoracic Cancer

Takahashi, Ken K; Seto, Yosuke Y; Okada, Koutaroh K; Uematsu, Shinya S; Uchibori, Ken K; Tsukahara, Mika M; Oh-Hara, Tomoko T; Fujita, Naoya N; Yanagitani, Noriko N; Nishio, Makoto M; Okubo, Kenichi K; Katayama, Ryohei R

Publication Date: 2020-03

Variant appearance in text: ALK: L1204V

PubMed Link: 31943796

Variant Present in the following documents:

• Main text
• TCA-11-581.pdf

View BVdb publication page

---

Sequential ALK Inhibitors Can Select for Lorlatinib-Resistant Compound ALK Mutations in ALK-Positive Lung Cancer.

Cancer Discovery

Yoda, Satoshi S; Lin, Jessica J JJ; Lawrence, Michael S MS; Burke, Benjamin J BJ; Friboulet, Luc L; Langenbucher, Adam A; Dardaei, Leila L; Prutisto-Chang, Kylie K; Dagogo-Jack, Ibiayi I; Timofeevski, Sergei S; Hubbeling, Harper H; Gainor, Justin F JF; Ferris, Lorin A LA; Riley, Amanda K AK; Kattermann, Krystina E KE; Timonina, Daria D; Heist, Rebecca S RS; Iafrate, A John AJ; Benes, Cyril H CH; Lennerz, Jochen K JK; Mino-Kenudson, Mari M; Engelman, Jeffrey A JA; Johnson, Ted W TW; Hata, Aaron N AN; Shaw, Alice T AT

Publication Date: 2018-06

Variant appearance in text: ALK: L1204V

PubMed Link: 29650534

Variant Present in the following documents:

• Main text

View BVdb publication page

---